NOVELIX PHARMACEUTICALS LIMITED Intrinsic Value
Valuation
Blended fair value using DCF and peer comparison methods.
NOVELIX PHARMACEUTICALS LIMITED Intrinsic Value Analysis
A current price is not available for NOVELIX PHARMACEUTICALS LIMITED (NOVELIX), so a price-to-value comparison cannot be shown. Understock's estimated intrinsic value is ₹28 per share.
The displayed estimate uses the available peer-based value of ₹28; a DCF estimate is not currently available. Peer comparison uses 8 matched industry companies and contributing P/E, P/B multiples.
For context, available company data reports P/E of 60.5×. These metrics describe the business and are not separate intrinsic-value estimates.
How Understock Calculates Intrinsic Value
Understock follows the company's stored valuation classification. Where DCF applies, the model discounts projected or normalized cash flows and terminal value using stored assumptions. Peer valuation compares available company multiples with medians from matched industry or sector companies, with a curated peer-group fallback where database matches are unavailable; the contributing multiples and their weights depend on sector rules and available data. For this page, the available displayed estimate comes from peer valuation. DCF and peer estimates can differ because they use different assumptions, financial metrics, and market reference points.
Review this company's DCF valuation · Learn how DCF works · Use the DCF calculator · See NOVELIX PHARMACEUTICALS LIMITED peer valuation · What intrinsic value means
The intrinsic value shown is an algorithmic estimate based on publicly available financial data — including DCF analysis, peer comparison, and historical financials. It is not a research report, investment advice, or a recommendation to buy, sell, or hold any security. Stock valuations involve uncertainty and may differ significantly from market prices. Please consult a SEBI-registered investment adviser before making any investment decision.
NOVELIX PHARMACEUTICALS LIMITED Peer Comparison
How this company stacks up against sector peers on valuation and quality metrics.
Healthcare · 8 peers · sector medians shown
| Company | Mkt Cap | P/E | P/B | EV/EBITDA | ROE | Net Margin | Rev CAGR 3y |
|---|---|---|---|---|---|---|---|
NOVELIX PHARMACEUTICALS LIMITED NOVELIX · you | ₹184 Cr | 60.5× | 24.4× | — | 40.4% | 0.0% | — |
| Sector median | — | 30.5× | 4.3× | 22.7× | 15.1% | 10.6% | 13.2% |
| Shukra Pharmaceuticals Limited SHUKRAPHAR | ₹1,821 Cr | 50.5× | 33.7× | — | 66.4% | 0.6% | — |
| Krsnaa Diagnostics Limited KRSNAA | ₹1,771 Cr | 18.0× | 1.8× | 8.6× | 10.3% | 13.1% | 16.6% |
| NGL Fine-Chem Limited NGLFINE | ₹1,744 Cr | 44.1× | 6.5× | 22.7× | 14.6% | 9.6% | 21.7% |
| Shalby Limited SHALBY | ₹1,658 Cr | 14.8× | 1.5× | — | 10.2% | 0.1% | — |
| Jagsonpal Pharmaceuticals Limited JAGSNPHARM | ₹1,566 Cr | 36.5× | 5.6× | 26.1× | 15.6% | 15.0% | 6.7% |
| Amrutanjan Health Care Limited AMRUTANJAN | ₹1,502 Cr | 24.5× | 3.8× | 19.8× | 15.6% | 11.5% | 9.8% |
| Syncom Formulations (India) Limited SYNCOMF | ₹1,402 Cr | 16.6× | 4.5× | — | 27.2% | 0.2% | — |
| Gujarat Kidney And Super Speciality Limited GKSL | ₹1,266 Cr | 54.7× | 4.3× | 44.8× | 6.1% | 18.9% | — |
NOVELIX trades at a premium to peers (P/E 60.5× vs median 30.5×), but its higher ROE of 40.4% (sector 15.1%) justifies much of that premium — quality rarely comes cheap.
Business quality
Valuation
Returns
Growth
Efficiency
Liquidity & Solvency
Financial health
Piotroski F-Score, Altman Z-Score, and key solvency ratios.
Full financial data
Charts and annual statements for income, balance sheet and cash flow.
Income trend
Revenue, profit and margin trends over time.
Cash flow
Where cash comes from and where it goes.
Balance sheet
Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.